Effect of primary prevention on major adverse cardiac event in breast cancer patients on cytotoxic chemotherapy
Among breast cancer patients receiving cytotoxic chemotherapy, primary prevention with cardioprotective pharmacological therapy was significantly associated with prolonged time to major adverse cardiovascular events, which support proactive cardioprotective strategies to mitigate treatment-related cardiovascular risk and reinforce the value of integrating preventive cardiology into cardio-oncology care pathways.